An endothelial SOX18–mevalonate pathway axis enables repurposing of statins for infantile hemangioma
Journal of Clinical Investigation · 01.04.2025 · 135 (7)
DOI: 10.1172/jci179782 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 25.02.2025. Verfasst von Annegret Holm und 19 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Biology Program, Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Hemangioma, Hydroxymethylglutaryl-CoA Reductase Inhibitors, SOXF Transcription Factors, Drug Repositioning. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health, National Health and Medical Research Council.
Abstract (Originalsprache)
Infantile hemangioma (IH) is the most common tumor in children and a paradigm for pathological vasculogenesis, angiogenesis, and regression. Propranolol, the mainstay of treatment, inhibits IH vessel formation via a β-adrenergic receptor-independent off-target effect of its R(+) enantiomer on endothelial SOX18 - a member of the SOX (SRY-related HMG-box) family of transcription factors. Transcriptomic profiling of patient-derived hemangioma stem cells uncovered the mevalonate pathway (MVP) as a target of R(+) propranolol. Loss and gain of function of SOX18 confirmed it is both necessary and sufficient for R(+) propranolol suppression of the MVP, including regulation of sterol regulatory element–binding protein 2 (SREBP2) and the rate-limiting enzyme HMG-CoA reductase (HMGCR). A biological relevance of the endothelial SOX18-MVP axis in IH patient tissue was demonstrated by nuclear colocalization of SOX18 and SREBP2. Functional validation in a preclinical IH xenograft model revealed that statins — competitive inhibitors of HMGCR — efficiently suppress IH vessel formation. We propose an endothelial SOX18-MVP axis as a central regulator of IH pathogenesis and suggest statin repurposing to treat IH. The pleiotropic effects of R(+) propranolol and statins along the SOX18-MVP axis to disable an endothelial cell–specific program may have therapeutic implications for other vascular disease entities involving pathological vasculogenesis and angiogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vascular Biology Program, Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- The David Richmond Laboratory for Cardiovascular Development: Gene Regulation and Editing, Centenary Institute, University of Sydney, Camperdown, New South Wales, Australia.
- Research Computing, Information Technology, Boston Children's Hospital, Boston, Massachusetts, USA.
- Human Molecular Genetics, de Duve Institute, University of Louvain, VASCERN-VASCA European Reference Center, Brussels, Belgium.
- Department of Dermatology, Lucile Packard Children's Hospital at the Stanford University School of Medicine, Palo Alto, California, USA.
- WELBIO Department, WEL Research Institute, Wavre, Belgium.
Förderung
- NHLBI NIH HHS
- National Institutes of Health
- National Health and Medical Research Council
- Nanyang Technological University CN Yang Scholars Program
- German Research Foundation
Zitieren
APA
Holm, A., Graus, M. S., Wylie-Sears, J., Tan, J. W. H., Alvarez-Harmon, M., Borgelt, L., Nasim, S., Chung, L., Jain, A., Sun, M., Sun, L., Brouillard, P., Lekwuttikarn, R., Qi, Y., Teng, J., Vikkula, M., Kozakewich, H., Mulliken, J. B., Francois, M., & Bischoff, J. (2025). An endothelial SOX18–mevalonate pathway axis enables repurposing of statins for infantile hemangioma. Journal of Clinical Investigation, 135(7). https://doi.org/10.1172/jci179782
Vancouver
Holm A, Graus MS, Wylie-Sears J, Tan JWH, Alvarez-Harmon M, Borgelt L, et al. An endothelial SOX18–mevalonate pathway axis enables repurposing of statins for infantile hemangioma. Journal of Clinical Investigation. 2025;135(7). doi:10.1172/jci179782
BibTeX
@article{Holm2025,
author = {Holm, Annegret and Graus, Matthew S and Wylie-Sears, Jill and Tan, Jerry Wei Heng and Alvarez-Harmon, Maya and Borgelt, Luke and Nasim, Sana and Chung, Long and Jain, Ashish and Sun, Mingwei and Sun, Liang and Brouillard, Pascal and Lekwuttikarn, Ramrada and Qi, Yanfei and Teng, Joyce and Vikkula, Miikka and Kozakewich, Harry and Mulliken, John B and Francois, Mathias and Bischoff, Joyce},
title = {An endothelial SOX18–mevalonate pathway axis enables repurposing of statins for infantile hemangioma},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {7},
doi = {10.1172/jci179782}
}
EUVIMED